Q-omics provides the consensus-scored PPA1 profile across patient tissues and cancer cell-line models. PPA1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, PPA1 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, PPA1 RNA expression shows 18,983 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where PPA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPA1 survival associations across molecular data types. PPA1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPA1 RNA expression–survival associations across cancer types. High PPA1 expression shows unfavorable associations in ACC, UVM, PAAD and LIHC, but favorable associations in SKCM and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for PPA1 RNA expression.
This table summarizes PPA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for PPA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPA1 shows lower tumor expression in KICH and higher tumor expression in COAD, LIHC, STAD, CHOL and READ. The COAD box plot shows higher PPA1 RNA expression in tumor versus normal tissue (log2 FC = +1.347, t-test p < 0.001).
This table shows molecular features associated with PPA1 in patient tissues and cancer cell lines. In patient samples, PPA1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SKIN and CNS.
